GaBI Educational Forum aims to enhance the knowledge on and understanding of key issues relating to regulatory approval and quality assessment of and good manufacturing practice for biologicals/biosimilars, as well as associated topics such as good manufacturing practices, clinical trials, interchangeability, pharmacovigilance, registries in biologicals/biosimilars.
The events are organized in collaboration with either the regulatory authority or reputable academic institution for regulators, academics, medical practitioners/specialists and health system stakeholders from different countries and regions.
To further share information and expertise, all speakers’ presentations are available online, and the meeting report of each event is published in GaBI Journal to document the discussions and learning.
By end of 2024, the GaBI Educational Forum has provided a productive and open learning environment in 12 countries over three continents to 897 key participants from 38 countries on focus key topics of biologicals/biosimilars, offering a discussion forum for national, regional and international colleagues to explore ways to communicate the biosimilars concept to physicians and patients.
Virtual educational workshops/scientific meetings/conferences for clinicians/physicians, academics, regulators and other stakeholders on nomenclature of biologicals, regulatory standards on biosimilars, non-medical switching, success factors of biosimilars uptake are being delivered in 2025. Contact us for more information.
Webinars
View the latest webinars GaBI organized:
BIOSIMILAR RED TAPE ELIMINATION ACT (S2305): Weakening FDA Regulatory Standards for Biosimilars, Undermining Physician Confidence and Jeopardizing Patient Health, 31 October 2024
INTERCHANGEABILITY DESIGNATION FOR BIOSIMILARS: Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars, 30 November 2023
• contact us for the webinar speakers’ presentations
MEDICARE DRUG PRICE NEGOTIATIONS: impact on healthcare development and patient access to medicines, 26 July 2023
GaBI educational workshops aim to provide training opportunities in focus topics identified by members of the journal editorial boards, reflecting the current educational needs of the target audience. Workshop topics in areas such as bioequivalence methodology, biopharmaceutical production, quality evaluation in general and generic drug evaluation in particular health economics, drug substitution issues and risk management programmes. GaBI educational workshops are delivered by recognized experts and are open to an international audience to promote common understanding and practical approach on the issues discussed in view of the GaBI mission: building trust in cost-effective treatments.
By end of 2024, GaBI has delivered 12 educational workshops in Belgium, Colombia, Indonesia, Malaysia, Mexico, Thailand, Turkey, Vietnam and UAE.
If you have any suggestions on generics and biosimilars scientific developments with appealing topics for an educational workshop, please contact us for further discussion.
View the latest educational workshops GaBI organized:
1st ASEAN Overview Workshop on GMP for BIOLOGICALS/BIOSIMILARS 2018
GaBI organizes and supports the organization of scientific conferences that advocate the importance of advancing generic and biosimilar medicines as the high quality, affordable, accessible and sustainable healthcare alternative. Authoritative figures and leaders in the scientific field of generics and biosimilars will be invited as guest speakers to share their views, or to communicate outcomes of original research, to an international audience.
By end of 2024, GaBI has organized seven scientific meetings in Belgium, Cambodia, Colombia, Saudi Arabia, Spain, UAE, and the UK.
View the latest scientific conferences/meetings GaBI organized:
2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars 2018
GaBI Journal is an independent and peer reviewed academic journal. GaBI Journal encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies.
